Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05518435
Other study ID # 313424
Secondary ID MHF008
Status Recruiting
Phase
First received
Last updated
Start date September 28, 2022
Est. completion date June 30, 2024

Study information

Verified date November 2023
Source University of Exeter
Contact Anna Price, PhD
Phone 01392726026
Email a.price@exeter.ac.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: Attention deficit hyperactivity disorder (ADHD) is the most common childhood neurodevelopmental disorder. It affects around 5% of children and adolescents, and up to 40% continue to experience symptoms into adulthood. Primary care practitioners (e.g., general practitioners (GPs), nurses, link workers, clinical pharmacists) play an important role in the healthcare of young people (YP) with ADHD, particularly due to long waiting times in adult mental health services, and patchy provision of specialist services. However, many practitioners feel unsure about how to support YP at this vulnerable stage in their lives. Practitioners report concerns about prescribing ADHD medication and a desire for more guidance. Currently, little is known about how YP with ADHD are supported in primary care, the strengths and weakness of existing care pathways, and how care can be improved. Aims: To provide an evidence-base by mapping current services, and co-produce guidance to improve and better co-ordinate primary care for YP aged 16-25 with ADHD. Methods: Three interlinked studies. A mapping study including a national survey of stakeholders to map patient pathways, prescribing practice, shared-care arrangements, and practitioner roles. A qualitative study including semi-structured interviews with YP and practitioners, to gain insight into experiences of 'what works' and 'what is needed'. Workshops to co-develop a map of patient pathways, key messages, and clinical guidance. Patient Involvement: This research has been developed in response to identified gaps in services, and requests from people with ADHD. The team includes young people with ADHD whose input will help ensure the research is sensitive and relevant, and an academic GP to ensure identified solutions are deliverable within primary care settings. Impact: The expected impact of this research is improvement of the quality and experience of care for YP with ADHD. Also, to improve experiences of primary care providers facing difficulties managing ADHD.


Description:

This research aims to map current services and co-create evidence-based guidance to improve and better co-ordinate primary care for young people aged 16-25 years with ADHD. OBJECTIVES The objectives of this research are to: 1. Develop a national map and overview of current primary care pathways and prescribing practice in the management of young people with ADHD 2. Explore: 1. Primary care providers and related organisations' needs for information resources and prescribing support in their roles managing care for young people with ADHD 2. The expectations and needs of young people aged 16-25 regarding primary care ADHD support, information, and management 3. Co-produce evidence informed guidance to better co-ordinate primary care for young people with ADHD, based on discussions around findings from objectives 1, 2a and 2b OUTCOMES The outcomes of this research will be shaped by close work with professionals and members of the community, via the practice and policy research advisory group (P-RAG) and young person and parent/carer research advisory group (Y-RAG) groups, to ensure their relevance and utility. Anticipated outcomes include: 1. National overview of primary care provision for young people with ADHD across England, including: 1. Geographic map, showing variation in provision by NHS region or appropriate organisational boundaries 2. Summary of existing care pathways for the management of young people with ADHD in primary care, including exemplars of best practice 2. Qualitative summary of the perspectives of people involved in delivering and in need of care, on the management of ADHD in primary care including: 1. Health professionals' needs for information resources and prescribing support 2. Young people with ADHD and their parent/carers' needs for information resources, healthcare, and support with self-management 3. Co-produced guidance on how to better co-ordinate and design primary care for young people aged 16-25 with ADHD. STUDY DESIGN and METHODS Overview: This mixed methods study consists of three work packages. Each WP involves data collection/creation working with the following stakeholder groups. - Patients, with a focus on young people (aged 16-25) with ADHD, and their parent/carers - Health professionals, with a focus on those in primary care (including general practitioners (GPs), specialist nurses, mental health practitioners, and clinical pharmacists) - Commissioners/providers of NHS healthcare for people with ADHD


Recruitment information / eligibility

Status Recruiting
Enrollment 278
Est. completion date June 30, 2024
Est. primary completion date March 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 16 Years and older
Eligibility Participants will include people aged 16 or over with lived experience of ADHD (and their parent/carers), health professionals with a focus on primary care (such as GPs, nurses, mental health practitioners, and clinical pharmacists), and primary care commissioners/providers. Sampling, recruitment strategies, and eligibility criteria, vary slightly between work packages, as outlined below. WP1 SURVEY Inclusion Criteria: Self-identifies as - Being at least one of the following: - A person aged 16 or over with lived experience of ADHD, or parent/carer of a person with ADHD - Health professional (person working in any role that provides healthcare services, include NHS, voluntary and private services, clinical, managerial, leadership and administrative roles) - Commissioner/provider of National Health Service (NHS) healthcare services (e.g., member of clinical commissioning group, primary care network (PCN), integrated care system (ICS), or another NHS organisation) - Currently resident, working, or studying in England Exclusion Criteria: - Does not identify as a person aged 16 or over with lived experience of ADHD, a health professional, or a commissioner/provider of NHS health services - Not currently resident, working, or studying in England WP2 QUALITATIVE STUDY Inclusion Criteria: - One of the following: - Young person aged 16-25 with lived experience of ADHD, or a parent/carer of a young person with ADHD - Health professional (person that provides healthcare services with a focus on primary care, including clinical, managerial, leadership and administrative roles) - Commissioner/provider of healthcare services (e.g., member of clinical commissioning group, PCN, ICS, NHS, or another organisation) - Currently resident or working in England - Currently resident or working close to one of the qualitative study sites identified following WP1, where 'close to' means located within the same geographic locality (to be decided based on findings from WP1) Exclusion Criteria: - Not a young person aged 16-25 with lived experience of ADHD (or a parent/carer), a health professional, or commissioner/provider of health services - Not currently resident or working in England - Not currently resident, working, or studying close to one of the qualitative study sites identified following WP1, where 'close to' means located within the same geographic locality (to be decided based on findings from WP1) WP3 Co-PRODUCTION Inclusion Criteria: - One of the following: - Young person aged 16-25 with lived experience of ADHD, or a parent/carer of a young person with ADHD - Health professional (person that provides healthcare services, including clinical, managerial, leadership and administrative roles) - Commissioner/provider of NHS healthcare services (e.g., member of clinical commissioning group, PCN, ICS, local authority, or another NHS organisation) - A member of the MAP study research team - Currently resident, working, or studying in England - Willing and able to work collaboratively and engage in consultations to co-produce evidence-based guidance for improving the co-ordination of primary care for young people with ADHD Exclusion Criteria: - Not a young person aged 16-25 with lived experience of ADHD (or a parent/carer), a health professional, commissioner/provider of NHS health services, or a member of the MAP study research team - Not currently resident, working, or studying in England - Not willing and able to work collaboratively and engage in consultations to co-produce evidence-based guidance for improving the co-ordination of primary care for young people with ADHD

Study Design


Related Conditions & MeSH terms


Intervention

Other:
None, observational study
The MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3).

Locations

Country Name City State
United Kingdom Anna Price Exeter Devon

Sponsors (1)

Lead Sponsor Collaborator
University of Exeter

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other WP3: Co-produced guidance on how to better co-ordinate and design primary care for young people aged 16-25 with ADHD. WP3 (co-production study) will deliver an output in the form of co-produced guidance on how to better co-ordinate and design primary care for young people aged 16-25 with ADHD. At time of co-production workshops
Primary WP1: Reports of the prescribing of adult ADHD medication, by primary care practices in England WP1 (national survey) will report on prescribing of ADHD medication by primary care practices in England. Outcome data will be communicated as a summary total of 'yes' / 'no' survey responses, and analysed by the geographic location of practices, as well as the type of respondent reporting this practice (e.g., person with ADHD, clinician, or commissioner) At time of completing survey
Secondary WP1: Reports of shared care agreements being in place for prescribing of adult ADHD medication, by local primary care practices (in England) WP1 (national survey) will report on the presence of shared care agreements for prescribing of ADHD medication by primary care practices in England. Outcome data will be communicated as a summary total of 'yes' / 'no' survey responses, and analysed by the geographic location of practices, as well as the type of respondent reporting this practice (e.g., person with ADHD, clinician, or commissioner) At time of completing survey
Secondary WP1: Reports of mental health support being in place for patients with adult ADHD medication, by local primary care practices (in England) WP1 (national survey) will report on the presence of shared care agreements for prescribing of ADHD medication by primary care practices in England. Outcome data will be communicated as a summary total of 'yes' / 'no' survey responses, and analysed by the geographic location of practices, as well as the type of respondent reporting this practice (e.g., person with ADHD, clinician, or commissioner) At time of completing survey
Secondary WP2: Qualitative summary of the perspectives of people involved in delivering and in need of care, on the management of ADHD in primary care medication, by local primary care practices (in England) WP2 (qualitative study) will report on experiences of primary care provision for young people with ADHD across England, from the perspectives of health professionals and young people with ADHD. Topics covered will include, prescribing practice, shared care agreements, and information provision. At time of interview
See also
  Status Clinical Trial Phase
Completed NCT03148782 - Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase N/A
Recruiting NCT06038942 - Formal Versus Informal Mindfulness Among University Students With Self-reported ADHD, Nonsuicidal Self-injury, or Stress N/A
Active, not recruiting NCT04978792 - Does Cultivating Self-compassion Improve Resilience to Criticism and Improve Mental Health in Adults With ADHD? N/A
Completed NCT03216512 - Effects of Noise Cancelling Headphones on Neurocognitive and Academic Outcomes in ADHD N/A
Not yet recruiting NCT02906501 - Effect of Risperidone on Cognitive Functions in Adolescents With ADHD and Behavioral Disturbances N/A
Completed NCT02900144 - Modified Comprehensive Behavioral Intervention for Tics (M_CBIT) N/A
Completed NCT02829528 - Little Flower Yoga for Kids: Evaluation of a Yoga and Mindfulness Program for Children With Increased Levels of Emotion Dysregulation and Inattention N/A
Completed NCT02562469 - ACTIVATE: A Computerized Training Program for Children With ADHD N/A
Terminated NCT02271880 - Improving Medication Adherence in ADHD Adolescents N/A
Recruiting NCT02255565 - Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study Phase 4
Completed NCT02463396 - Mindfulness Training in Adults With ADHD N/A
Completed NCT01673594 - Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist Phase 4
Terminated NCT01733680 - Amiloride Hydrochloride as an Effective Treatment for ADHD Early Phase 1
Completed NCT02300597 - Internet-based Support for Young People With ADHD and Autism - a Controlled Study N/A
Active, not recruiting NCT01137318 - Combined Cognitive Remediation and Behavioral Intervention for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD) Phase 2
Completed NCT01404273 - Functional MRI of Relaxation Response Training in Adults With Attention-Deficit/Hyperactivity Disorder N/A
Completed NCT00586157 - Study of Medication Patch to Treat Children Ages 6-12 With ADHD Phase 4
Completed NCT00573859 - The Reinforcing Mechanisms of Smoking in Adult ADHD Phase 1/Phase 2
Completed NCT00228540 - Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD Phase 3
Completed NCT00190736 - Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months) Phase 4